Gral Medical S.R.L.
- Address
- Spitalul Oncofort, Aleea Doctor Ana Aslan Nr 15, 110283 Bucharest, Romania
Neoplasms (Oncology)
Gral Medical S.R.L. conducts a broad portfolio of oncology studies aimed at improving outcomes for patients with solid tumors such as melanoma, breast cancer, ovarian cancer, and head and neck cancer. The trials evaluate new targeted agents, immunotherapy combinations, and advanced endocrine strategies to enhance survival and reduce recurrence.
- Combination immunotherapy for advanced melanoma
- Novel endocrine therapy versus standard adjuvant treatment in early breast cancer
- HER2‑directed antibody‑drug conjugate paired with anti‑angiogenic therapy for ovarian cancer
- Hormone‑sensitive prostate cancer regimens incorporating next‑generation inhibitors
- Integrated biosimilar assessment of checkpoint inhibitors for head and neck squamous cell carcinoma
With a team of nine investigators, the site supports twelve active trials, fostering collaboration across surgical, medical, and radiation oncology disciplines to bring innovative therapies to patients in Bucharest and beyond.
Respiratory Tract Diseases
The research program at Gral Medical S.R.L. also focuses on non‑small cell lung cancer (NSCLC), including subpopulations with KRAS G12C mutations. Studies explore novel kinase inhibitors, immune‑checkpoint combinations, and chemotherapy‑free regimens to extend progression‑free survival and overall survival for patients with advanced disease.
- First‑line KRAS G12C‑mutant NSCLC targeted therapy combined with immunotherapy
- Ceralasertib plus durvalumab versus standard chemotherapy for advanced NSCLC
- FYB206 as an alternative to pembrolizumab in metastatic non‑squamous NSCLC
- BNT327 in combination with chemotherapy for lung cancer treatment
- Safety and dose‑optimization studies of LY3537982 with pembrolizumab and platinum agents
The site’s multidisciplinary approach leverages expertise from thoracic oncology and pulmonology, enabling rapid enrollment of patients across Romania and contributing valuable data to global lung‑cancer research initiatives.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 therapeutic areas and 15 of 27 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 6 by active trials.
- 1AstraZeneca AB2active
lock +5 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB3trials
lock +2 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 442 other sites in Romania
Therapeutic Area Benchmark — Romania
Select a therapeutic area to compare against other sites in Romania.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Romania
Market Share
Country: Romania
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Gral Medical S.R.L.
lock Showing 1 of 14 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Multicenter, Randomized, Double-Blind Study Comparing the Efficacy, Safety, and Immunogenicity of FYB206 and Pembrolizumab in Metastatic Non-Squamous NSCLC | Formycon AG | Phase III | Not Recruiting | — | Feb 2025 |
IMP list
lock Showing 1 of 27 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 6 | Unknown | 2023-02-09 | 2025-09-18 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.